Delcath Systems (NASDAQ:DCTH) Stock Price Crosses Above 50 Day Moving Average – Should You Sell?

Shares of Delcath Systems, Inc. (NASDAQ:DCTH) crossed above its 50-day moving average during trading on Monday. The stock has a 50-day moving average of $15.53 and traded as high as $20.30. Delcath Systems shares last traded at $20.27, with a volume of 3,448,393 shares traded.

Key Headlines Impacting Delcath Systems

Here are the key news stories impacting Delcath Systems this week:

• Positive Sentiment: For Q3 2026, Delcath reported earnings of $0.17 per share, versus analysts’ expected loss of about $0.09, and revenue of $35.1 million, ahead of the $26.0 million consensus estimate. Article: Delcath Systems Q3 Earnings and Revenues Top Estimates
• Positive Sentiment: The company projected FY 2026 revenue of $115 million to $117 million, above the analyst consensus of $106.2 million, and is targeting at least 36 active centers by year-end. Article: Delcath outlines 2026 revenue guidance and active-center target
• Positive Sentiment: BTIG Research raised its price target to $25 from $21 and maintained a Buy rating, signaling increased analyst confidence.

Wall Street Analyst Weigh In

A number of equities research analysts have recently commented on DCTH shares. BTIG Research upped their target price on shares of Delcath Systems from $21.00 to $25.00 and gave the company a “buy” rating in a report on Monday. Zacks Research cut shares of Delcath Systems from a “strong-buy” rating to a “hold” rating in a report on Tuesday, October 6th. HC Wainwright restated a “buy” rating and set a $32.00 price objective (up from $30.00) on shares of Delcath Systems in a research report on Friday, August 7th. Wall Street Zen raised Delcath Systems from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, Weiss Ratings downgraded shares of Delcath Systems from a “hold (c)” rating to a “hold (c-)” rating in a report on Wednesday, October 28th. Two analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $28.00.

Delcath Systems Trading Up 35.8%

The company has a market capitalization of $703.37 million, a PE ratio of 2,029.03 and a beta of 0.62. The business’s 50-day simple moving average is $15.53 and its two-hundred day simple moving average is $12.49.

Delcath Systems (NASDAQ:DCTH) last released its quarterly earnings results on Monday, November 9th. The company reported $0.17 EPS for the quarter, topping the consensus estimate of ($0.09) by $0.26. Delcath Systems had a return on equity of 0.46% and a net margin of 0.56%. The business had revenue of $35.10 million for the quarter, compared to analysts’ expectations of $25.99 million. On average, analysts forecast that Delcath Systems, Inc. will post -0.17 EPS for the current year.

Hedge Funds Weigh In On Delcath Systems

Several large investors have recently modified their holdings of the stock. Integrated Wealth Concepts LLC bought a new position in Delcath Systems during the 2nd quarter worth approximately $48,000. IFP Advisors Inc acquired a new position in Delcath Systems during the 2nd quarter valued at about $52,000. Royal Bank of Canada raised its holdings in Delcath Systems by 14.8% during the first quarter. Royal Bank of Canada now owns 18,383 shares of the company’s stock worth $170,000 after purchasing an additional 2,364 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in Delcath Systems during the first quarter valued at about $306,000. Finally, Sei Investments Co. grew its stake in shares of Delcath Systems by 100.0% in the 1st quarter. Sei Investments Co. now owns 44,058 shares of the company’s stock worth $409,000 after purchasing an additional 22,029 shares during the last quarter. Institutional investors own 61.12% of the company’s stock.

Delcath Systems Company Profile

Delcath Systems, Inc is a medical technology company focused on liver-directed cancer treatments. The company develops and commercializes systems designed to deliver high concentrations of chemotherapy to the liver while limiting exposure to the rest of the body.

Its primary product in the United States is the HEPZATO KIT, a liver-directed therapy that combines the company’s proprietary hepatic delivery system with melphalan hydrochloride for injection. HEPZATO is approved for the treatment of adult patients with unresectable metastatic uveal melanoma involving the liver, without extrahepatic disease or with limited extrahepatic disease that is not clinically significant.

Outside the United States, Delcath markets the corresponding system under the CHEMOSAT brand.